对瘤生长抑制模型的概率分析,以支持试验设计
Marcus Baaz1, Tim Cardilin2, Torbjörn Lundh3
1Fraunhofer-Chalmers Research Centre for Industrial Mathematics, Gothenburg, Sweden; Department of Mathematical Sciences, Chalmers University of Technology and University of Gothenburg, Gothenburg, Sweden.
确定临床试验的最佳患者样本大小至关重要. 本研究引入了一种新的参数模型,使用瘤生长抑制和RECIST标准来计算样本大小,平衡统计学意义与临床相关性和成本效益.
科学领域:
- 制药指标 (Pharmacometrics) 是一个指标.
- 生物统计学 生物统计学
- 临床试验设计 临床试验设计
背景情况:
- 准确的样本大小确定对于临床试验的效率和有效性至关重要.
- 典型的统计方法用于样本大小计算通常需要先前存在的治疗疗效数据,这对于新药来说是不可用的.
- 瘤生长抑制 (TGI) 模型对于量化抗癌药物疗效至关重要.
研究的目的:
- 开发一个参数模型,用于在临床试验中计算样本大小,比较两个治疗方法.
- 整合瘤生长抑制 (TGI) 模型和RECIST标准,以改进样本大小的确定.
- 将瘤静态暴露概念概括为更好的临床反应预测.
主要方法:
- 用TGI模型和RECIST标准来推导患者响应概率的分析表达式.
- 应用经典统计学来推导一个参数模型来计算样本大小.
- 瘤静态暴露概念的概括以及暴露和灵敏度表达式的推导.
主要成果:
- 开发了一个基于TGI和RECIST的样本大小计算的参数模型.
- 为患者对组合疗法的反应衍生了概率表达式.
- 扩展了瘤静态暴露概念,以提高临床反应预测.
结论:
- 拟议的模型为优化药物开发早期阶段样本大小选择提供了一个框架.
- 这种方法平衡了统计学严谨性,临床相关性和经济考虑.
- 一般化的瘤静态暴露提供了对临床结果的更具预测性的测量方法.
更多相关视频
09:24Generation of Microtumors Using 3D Human Biogel Culture System and Patient-derived Glioblastoma Cells for Kinomic Profiling and Drug Response Testing
Published on: June 9, 2016
09:32Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
Published on: February 8, 2018
相关概念视频
Cancer Survival Analysis
Comparing the Survival Analysis of Two or More Groups
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Assumptions of Survival Analysis
Kaplan-Meier Approach
Parametric Survival Analysis: Weibull and Exponential Methods
Weibull Distribution
The Weibull distribution is a flexible model used in parametric survival analysis. It can handle both increasing and decreasing hazard rates, depending on its shape parameter...
